Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.
Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, Yanagiya S, Miya A, Kameda H, Cho KY, Sakuma I, Manda N, Nakamura A, Atsumi T. Nomoto H, et al. Among authors: oe y. Pharmaceutics. 2023 Jun 27;15(7):1838. doi: 10.3390/pharmaceutics15071838. Pharmaceutics. 2023. PMID: 37514025 Free PMC article.
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.
Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H. Oe Y, et al. J Diabetes Res. 2022 Jan 19;2022:5603864. doi: 10.1155/2022/5603864. eCollection 2022. J Diabetes Res. 2022. PMID: 35097130 Free PMC article.
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Takahashi A, Nomoto H, Yokoyama H, Yokozeki K, Furusawa S, Oe Y, Kameda R, Kawata S, Miyoshi A, Nagai S, Miya A, Kameda H, Nakamura A, Atsumi T; MEGMI study group. Takahashi A, et al. Among authors: oe y. Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16150. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 39726204
Deep learning-based histopathological assessment of tubulo-interstitial injury in chronic kidney diseases.
Suzuki N, Kojima K, Malvica S, Yamasaki K, Chikamatsu Y, Oe Y, Nagasawa T, Kondo E, Sanada S, Aiba S, Sato H, Miyazaki M, Ito S, Sato M, Tanaka T, Kinoshita K, Asano Y, Rosenberg AZ, Okamoto K, Shido K. Suzuki N, et al. Among authors: oe y. Commun Med (Lond). 2025 Jan 5;5(1):3. doi: 10.1038/s43856-024-00708-3. Commun Med (Lond). 2025. PMID: 39757253 Free PMC article.
Discriminant analysis of occupational performance characteristics in patients with major depressive disorders and healthy individuals.
Hayasaka T, Nagashima I, Hoshino M, Teruya K, Matumoto Y, Murao M, Maruki T, Watanabe M, Katagiri T, Imamura Y, Kurihara M, Oe Y, Takaesu Y, Tsuboi T, Watanabe K, Sakurai H. Hayasaka T, et al. Among authors: oe y. PCN Rep. 2024 Nov 26;3(4):e70038. doi: 10.1002/pcn5.70038. eCollection 2024 Dec. PCN Rep. 2024. PMID: 39605926 Free PMC article.
174 results